Optimizing Biotech-CRO Collaboration in Early Drug Discovery: Trends, Challenges, and Solutions
The webinar titled "Optimizing Biotech-CRO Collaboration in Early Drug Discovery" will examine current trends, challenges, and solutions in outsourcing early drug discovery research from small to midsize biotech companies to CROs, featuring research and survey data from the American Chemical Society and offering practical strategies to enhance collaboration efficiency and success.
Join us for an insightful webinar on optimizing the collaboration between biotech companies and contract research organizations (CROs) in early drug discovery. As pharmaceutical innovation continues to be driven by small to midsize biotechs, the strategic outsourcing of research and development activities to CROs has become crucial for navigating the challenges faced by these companies.
This webinar will explore the latest trends and challenges in early drug discovery outsourcing, backed by research and survey findings commissioned by Dotmatics from the American Chemical Society.
We will delve into the evolving role of CROs and discuss how biotech-CRO collaboration can be optimized to achieve maximum efficiency and success.
Don't miss this opportunity to gain valuable insights and practical strategies for optimizing your biotech-CRO collaborations in early drug discovery.
Related
Three Real-World Examples of Smarter Biotech-CRO Outsourcing in Action
The article highlights how Dotmatics’ Biotech-CRO portal enhances early drug discovery outsourcing by enabling secure, efficient data exchange and project management, exemplified by Cereval’s use of the platform to streamline compound upload and registration between internal scientists and CROs while maintaining strict access controls.
Webinar: How to profit from recent innovations in small molecule drug discovery
The webinar, led by Dotmatics’ Director of Product Marketing Haydn Boehm on September 29 at 14:00 BST, will explore the resurgence and innovation in small molecule drug discovery, addressing current research landscapes, challenges, and strategies for optimizing data integration and workflows to accelerate drug candidate identification and reduce costs.
Dotmatics Appoints Mike McKee as President and CEO
Dotmatics Ltd has appointed experienced technology CEO Mike McKee as its new President to accelerate the company's growth, scale its global team, double R&D investments, and lead integration efforts within Insightful Science's portfolio, succeeding founder Stephen Gallagher who will focus on strategic growth initiatives.
From Outsourcing Synthesis to Driving Innovation: How CROs Transformed Small Molecule R&D
The article explains how contract research organizations (CROs) transformed small molecule drug discovery by helping pharmaceutical and biotech companies control escalating R&D costs and overcome innovation slowdowns through outsourcing synthesis, expanding capacity, providing specialized expertise, and offering access to advanced technologies, thereby evolving from optional service providers into essential partners driving growth and innovation in the industry.
How Biotechs Can Streamline Multi-CRO Collaboration in Early Small Molecule Drug Discovery
A recent survey by C&EN BrandLab reveals that biotechs, facing funding challenges post-COVID, are increasingly outsourcing a broad range of early small molecule drug discovery tasks—beyond synthesis—to multiple CROs, with many engaging over five providers, highlighting a growing trend to optimize R&D by leveraging multi-CRO collaborations despite this area being less studied compared to clinical-phase outsourcing.
Simplify your laboratory workflow management with Dotmatics
Dotmatics offers a unified scientific R&D platform that streamlines laboratory workflow management by integrating various scientific applications, automating data extraction, cleaning, and harmonization into FAIR formats, thereby reducing manual data handling, enhancing collaboration, and accelerating the R&D cycle to help life sciences organizations bring new therapies to market faster.